Alexander O. Schuth, Chief Financial Officer and Secretary of Denali Therapeutics Inc. (NASDAQ:DNLI), filed a Form 4 on September 3, 2026, disclosing the sale of 2,768 shares of common stock on September 1, 2026.

Key Highlights

  • Transaction: Schuth disposed of 2,768 shares of Denali Therapeutics common stock at $23.44 per share on September 1, 2026.
  • 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.
  • Direct holdings after transaction: Schuth directly beneficially owned 278,995 shares following the reported sale, including 135,475 unvested RSUs.
  • Indirect holdings: An additional 523,749 shares are held indirectly through The Schuth Family Trust U/A DTD 06/05/2017, for which Schuth serves as trustee.
  • Role: Schuth is identified in the filing as COFO and Secretary of Denali Therapeutics Inc.

Schuth's September 2026 Share Disposal at Denali Therapeutics

According to the filing, Alexander O. Schuth sold 2,768 shares of Denali Therapeutics Inc. common stock on September 1, 2026, at a price of $23.44 per share. The filing indicates the transaction was carried out under a Rule 10b5-1 trading plan that Schuth adopted on March 27, 2026. The Form 4 was signed by Tyler Nielsen by power of attorney and filed on September 3, 2026.

Following the reported sale, the filing discloses that Schuth directly beneficially owned 278,995 shares of common stock, a figure that the filing notes includes 135,475 unvested RSUs. Separately, the filing reports that 523,749 shares are held indirectly, with the filing identifying the record holder as The Schuth Family Trust U/A DTD 06/05/2017, for which Schuth serves as trustee.

The filing indicates the transaction box was checked to reflect that it was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as described in Instruction 10 of the form.

What Was Disclosed

Denali Therapeutics COFO and Secretary Alexander O. Schuth reported a sale of 2,768 shares of common stock at $23.44, executed under a pre-established 10b5-1 plan, leaving him with 278,995 shares directly and 523,749 shares indirectly held.